● Brings together Recursion's scaled biology exploration and translational capabilities with Exscientia's precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platform . Combined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methods · Highly complementar ...